Pevonedistat Alone & in Combination With Chemotherapy in Patients With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01950572` - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated	`NCT01624090` - Mithramycin for Lung, Esophagus, and Other Chest Cancers	Phase 2
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05415098` - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas	Phase 1
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT06057935` - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2
Terminated	`NCT02838745` - Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Recruiting	`NCT01912547` - Thromboelastography During Surgery for Malignant Pleural Mesothelioma	Phase 0
Completed	`NCT01521325` - A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers	Phase 1
Recruiting	`NCT00996385` - Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma	Phase 2
Recruiting	`NCT02073500` - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Completed	`NCT02467426` - Isolated Thoracic Perfusion (ITP-F) for MPM	Phase 2
Completed	`NCT00407459` - Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00787410` - An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma	Phase 2
Terminated	`NCT01907100` - Nintedanib (BIBF 1120) in Mesothelioma	Phase 2/Phase 3
Completed	`NCT04056026` - A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma	Early Phase 1
Completed	`NCT02903914` - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03685591` - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03683680` - Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers	N/A

NCT number	NCT03319537
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	October 5, 2017
Completion date	June 5, 2023

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms